| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Radiation Oncology, Vanderbilt University Medical Centre; 2 Vanderbilt-Ingram Cancer Center, School of Medicine, Vanderbilt University, Nashville, Tennessee; 3 Washington University School of Medicine, St. Louis, Missouri; 4 Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; 5 National Heart Lung and Blood Institute, Bethesda, Maryland; and 6 Department of Cell Biology and Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
Requests for reprints: Fen Xia, Department of Radiation Oncology, Vanderbilt University Medical Center, 1301 22nd Avenue South, Nashville, TN 37232. Phone: 615-322-2555; Fax: 615-343-6589; E-mail: fen.xia{at}vanderbilt.edu.
The tumor suppressor gene BRCA1 maintains genomic integrity by protecting cells from the deleterious effects of DNA double-strand breaks (DSBs). Through its interactions with the checkpoint kinase 2 (Chk2) kinase and Rad51, BRCA1 promotes homologous recombination, which is typically an error-free repair process. In addition, accumulating evidence implicates BRCA1 in the regulation of nonhomologous end-joining (NHEJ), which may involve precise religation of the DSB ends if they are compatible (i.e., error-free repair) or sequence alteration upon rejoining (i.e., error-prone or mutagenic repair). However, the precise role of BRCA1 in regulating these different subtypes of NHEJ is not clear. We provide here the genetic and biochemical evidence to show that BRCA1 promotes error-free rejoining of DSBs in human breast carcinoma cells while suppressing microhomology-mediated error-prone end-joining and restricting sequence deletion at the break junction during repair. The repair spectrum in BRCA1-deficient cells was characterized by an increase in the formation of >2 kb deletions and in the usage of long microhomologies distal to the break site, compared with wild-type (WT) cells. This error-prone repair phenotype could also be revealed by disruption of the Chk2 phosphorylation site of BRCA1, or by expression of a dominant-negative kinase-dead Chk2 mutant in cells with WT BRCA1. We suggest that the differential control of NHEJ subprocesses by BRCA1, in concert with Chk2, reduces the mutagenic potential of NHEJ, thereby contributing to the prevention of familial breast cancers. (Cancer Res 2006; 66(3): 1401-8)
This article has been cited by other articles:
|
|
 |
|
  J. Yan, X.-P. Yang, Y.-S. Kim, and A. M. Jetten RAP80 Responds to DNA Damage Induced by Both Ionizing Radiation and UV Irradiation and Is Phosphorylated at Ser205 Cancer Res., June 1, 2008; 68(11): 4269 - 4276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huang, Z.-H. Miao, H. Zhu, Y.-J. Cai, W. Lu, and J. Ding Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins Mol. Cancer Ther., June 1, 2008; 7(6): 1440 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Kass, J. Ahn, T. Tanaka, W. A. Freed-Pastor, S. Keezer, and C. Prives Stability of Checkpoint Kinase 2 Is Regulated via Phosphorylation at Serine 456 J. Biol. Chem., October 12, 2007; 282(41): 30311 - 30321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lee and S. E. Lee Saccharomyces cerevisiae Sae2- and Tel1-Dependent Single-Strand DNA Formation at DNA Break Promotes Microhomology-Mediated End Joining Genetics, August 1, 2007; 176(4): 2003 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yan, Y.-S. Kim, X.-P. Yang, L.-P. Li, G. Liao, F. Xia, and A. M. Jetten The Ubiquitin-Interacting Motif Containing Protein RAP80 Interacts with BRCA1 and Functions in DNA Damage Repair Response Cancer Res., July 15, 2007; 67(14): 6647 - 6656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Das, B. P. Chen, M. D. Story, M. Sato, J. D. Minna, D. J. Chen, and C. S. Nirodi Somatic Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) Abrogate EGFR-Mediated Radioprotection in Non-Small Cell Lung Carcinoma Cancer Res., June 1, 2007; 67(11): 5267 - 5274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kuhfittig-Kulle, E. Feldmann, A. Odersky, A. Kuliczkowska, W. Goedecke, A. Eggert, and P. Pfeiffer The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV Mutagenesis, May 1, 2007; 22(3): 217 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Lord, M. D. Garrett, and A. Ashworth Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy Clin. Cancer Res., August 1, 2006; 12(15): 4463 - 4468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-C. Wang, W.-C. Chou, S.-Y. Shieh, and C.-Y. Shen Ataxia Telangiectasia Mutated and Checkpoint Kinase 2 Regulate BRCA1 to Promote the Fidelity of DNA End-Joining Cancer Res., February 1, 2006; 66(3): 1391 - 1400. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
